BRCA2 and pachyonychia congenita: The results of the systematic review are generally consistent with current screening recommendations that propose annual screening using EUS or MRI/MRCP for FDR of patients with PC from familial PC kindred with at least two affected FDRs, patients with PJS, and p16, BRCA2 and hereditary non-polyposis colorectal cancer mutation carriers with ≥1 affected FDR [12,15,19,21].